No Data
Stifel Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Cuts Target Price to $16
Express News | Black Diamond Therapeutics Inc : Stifel Cuts Target Price to $16 From $18
Strong Buy Rating for Black Diamond Therapeutics Driven by Financial Stability and Promising Clinical Developments
Express News | Black Diamond Therapeutics Inc: Clinical Updates of Bdtx-1535 in Egfrm Nsclc and Regulatory Feedback Expected in Q1 2025
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Black Diamond Theraptcs Cash, Cash Equivalents, and Investments of $112.7 M as of Sept 30 >BDTX
No Data
No Data